Rubrik, Inc. (RBRK)
NYSE: RBRK · Real-Time Price · USD
87.65
-7.30 (-7.69%)
At close: Aug 1, 2025, 4:00 PM
87.35
-0.30 (-0.34%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $98.59, which forecasts a 12.48% increase in the stock price over the next year. The lowest target is $40 and the highest is $125.
Price Target: $98.59 (+12.48%)
Analyst Consensus: Buy
* Price targets were last updated on Jun 12, 2025.
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 5 | 5 | 5 |
| Buy | 11 | 13 | 13 | 11 | 11 | 11 |
| Hold | 3 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 21 | 21 | 19 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $80 → $120 | Buy | Maintains | $80 → $120 | +36.91% | Jun 12, 2025 |
| CIBC | CIBC | Buy Maintains $110 → $125 | Buy | Maintains | $110 → $125 | +42.61% | Jun 9, 2025 |
| Roth Capital | Roth Capital | Strong Buy Maintains $97 → $107 | Strong Buy | Maintains | $97 → $107 | +22.08% | Jun 6, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $77 → $110 | Buy | Maintains | $77 → $110 | +25.50% | Jun 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $105 → $108 | Strong Buy | Maintains | $105 → $108 | +23.22% | Jun 6, 2025 |
Financial Forecast
Revenue This Year
1.21B
from 886.54M
Increased by 36.37%
Revenue Next Year
1.51B
from 1.21B
Increased by 24.81%
EPS This Year
-1.00
from -7.48
EPS Next Year
-0.53
from -1.00
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.2B | 1.6B | 2.1B |
| Avg | 1.2B | 1.5B | 1.9B |
| Low | 1.2B | 1.4B | 1.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 40.8% | 34.2% | 37.7% |
| Avg | 36.4% | 24.8% | 25.3% |
| Low | 30.6% | 17.1% | 14.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.00 | -0.04 | 0.50 |
| Avg | -1.00 | -0.53 | 0.22 |
| Low | -1.01 | -0.83 | -0.15 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.